Portland, Ore. — As chip dimensions shrink, picometer variability among nanoscale dimensions and the uneven distribution of dopants stand in the way of further miniaturization. Use of a precisely ...
A 4D Molecular Therapeutics, Inc. phase 2 PRISM study indicated that there was an 89% reduction in annualized injections when Wet-AMD patients were given a high dose of 4D-150; Phase 3 trial ...
4D Molecular Therapeutics Expands Leadership Team with Appointments and Promotions of Key Executives
EMERYVILLE, Calif.--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback